162
Participants
Start Date
April 30, 2008
Primary Completion Date
January 31, 2011
Study Completion Date
April 30, 2011
vandetanib induction
100 mg daily by mouth
Docetaxel
(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
Carboplatin
IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
Placebo
Vandetanib maintenance
300 mg daily by mouth
Montefiore Medical Center, The Bronx
Mount Nittany Medical Center, State College
Central PA Hematology & Medical Oncology Associaties, Lemoyne
Lancaster General Hospital, Lancaster
Hematology & Oncology of NEPA, Dunmore
Abington Memorial Hospital, Abington
University of Pennsylvania, Philadelphia
Albert Einstein Cancer Center, Philadelphia
The Reading Hospital and Medical Center, Reading
Greater Baltimore Medical Center, Baltimore
Charleston Area Medical Center, Charleston
Boca Raton Community Hospital, Boca Raton
Lakeland Regional Cancer Center, Lakeland
Meharry Medical College, Nashville
Aultman Hospital, Canton
St. Vincent Hospital, Green Bay
St. Joseph Mercy Hospital- Ann Arbor, Ann Arbor
West Michigan Cancer Center, Kalamazoo
Regional Cancer Center, Waukesha
Gundersen Lutheran, La Crosse
Metro-Minnesota CCOP, Saint Louis Park
Sanford Clinic, Sioux Falls
SwedishAmerican Hospital, Rockford
Cancer Center of Kansas, Wichita
Ochsner Clinic, New Orleans
University of Texas Southwestern Medical Center, Dallas
Ocean Medical Center, Brick
Morristown Memorial Hospital, Morristown
Cancer Institute of New Jersey, New Brunswick
Riverview Medical Center, Red Bank
Collaborators (1)
AstraZeneca
INDUSTRY
PrECOG, LLC.
OTHER